Skip to main content.

Currently Enrolling Studies

Help us advance our research mission. Here's how you can get involved.

The goal of all clinical research, and particularly clinical trials, is to discover new approaches to conditions currently without a treatment or to developing more effective treatment options. We are always looking for volunteers willing to join us on this journey. In fact, we couldn’t do it without you. Here are our currently enrolling studies:

PTSD

A 12-week Phase 3 double-blind clinical study of brexpiprazole with an option for rollover into open-label trial for treatment of PTSD.

  • Eligibility criteria: volunteers ages 18-65 with a confirmed diagnosis of PTSD for a minimum of six months before screening.

  • Principal investigator: Shilpa Sachdeva, M.D.

Adolescent schizophrenia

A six-week Phase 3 double-blind clinical study of brexpiprazole with option for open-label rollover for treatment of adolescent schizophrenia.

  • Eligibility criteria: volunteers ages 13-17 with a current primary diagnosis of schizophrenia or history (diagnosis or symptoms) of the disease for at least six months before screening.

  • Projected enrollment cut-off date: November 2021

  • Principal investigator: Sharon Cain, M.D.

Prader-Willi syndrome

Phase 3, randomized, double‑blind, placebo‑controlled study with diazoxide for the treatment of hyperphagia in Prader‑Willi syndrome (Soleno Therapeutics, Inc.)

  • Eligibility criteria: Children and adults up to 65 years, referrals appreciated
  • Enrollment start date: Fall 2018
  • Principal investigator: Merlin Butler, M.D., Ph.D.

Phase 2, randomized, double-blind, placebo-controlled pilot study to assess the effects of carbetocin on hyperphagia in Prader-Willi syndrome (Levo Therapeutics, Inc.)

  • Eligibility criteria: Ages 7-18
  • Enrollment: Closed (Study ongoing)
  • Principal investigator: Merlin Butler, M.D., Ph.D.

Phase 2/3, randomized, double‑blind, placebo‑controlled study for the treatment of hyperphagia in Prader‑Willi syndrome

  • Eligibility criteria: Children and adults up to 65 years, referrals appreciated
  • Projected enrollment start date: Fall 2021
  • Principal investigator: Ann Genovese, M.D. 

For more information about this study, contact Cyndi E. Brooks, APRN, Clinical Research Coordinator, at 913-588-1143 and cbrooks2@kumc.edu

Psychiatry and Behavioral Sciences

University of Kansas Medical Center
Psychiatry and Behavioral Sciences
Mailstop 4015
3901 Rainbow Boulevard
Kansas City, KS 66160
Phone: 913-588-6433
Fax: 913-588-6414